nach oben

Erschienen in:

13.12.2023 | Original Article

Lymphocyte subsets and soluble forms of MIC-A and MIC-B are prognostic factors in non-Hodgkin lymphoma patients

verfasst von: Ana Cristina Olivas-Bejarano, Laura Arcelia Montiel-Cervantes, Flor del Carmen Perez-Retiguin, Socrates Garcia-Gutierrez, Teresita Rocio Cruz-Hernandez, Ruth Angelica Lezama-Palacios, Elba Reyes-Maldonado, Jorge Vela-Ojeda

Erschienen in: Annals of Hematology | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

MIC-A and MIC-B are the natural ligands for NKG2D, an activator receptor expressed in NK cells. Soluble isoforms of MIC-A and MIC-B (sMICA, sMICB) have been identified in different malignancies, affecting NK cells’ cytotoxicity. The study was performed to determine the levels of sMICA, sMICB, the expression of MIC-A, and MIC-B on tumor tissues, and lymphocyte subpopulations (CD4 + , CD8 + , NK, NKT, Tγδ cells, B cells, monocytes) in 94 patients with non-Hodgkin's lymphoma (NHL) and 72 healthy donors.

The most frequent lymphoma was diffuse large B cell lymphoma (48%). Patients with NHL had decreased numbers of CD4 T cells, CD8 T cells, B cells, monocytes, NK cells, type 1 dendritic cells, γδ T cells, and increased iNKT cells. Patients showed higher levels of sMIC-A and similar serum levels of sMIC-B.

Survival was poorer in patients having higher LDH values and lower numbers of CD4 T cells, type 1 dendritic cells, gamma-delta T cells, and high levels of sMIC-A.

In conclusion, high levels of sMIC and decreased numbers in circulating lymphocyte subsets are related to poor outcomes in NHL.

Shankland KR, Armitage JO, Hancock BW (2012) Non-Hodgkin lymphoma. Lancet 380(9844):848–857. https://doi.org/10.1016/S0140-6736(12)60605-9CrossRefPubMed

Bowzyk Al-Naeeb A, Ajithkumar T, Beham S, Hodson DJ (2018) Non-Hodgkin lymphoma. Br Med J 362:k304. https://doi.org/10.1136/bmj.k3204CrossRef

Armitage JO, Gascoyne R, Lunning MA, Cavalli F (2017) Non-Hodgkin lymphoma. Lancet 10091:298–310. https://doi.org/10.1016/S0140-6736(16)32407-2CrossRef

López-Soto A, Huergo-Zapico L, Acebes-Huerta A, Villa-Alvarez M, Gonzalez S (2015) NKG2D signaling in cancer immunosurveillance. Int J Cancer 136:1741–1750. https://doi.org/10.1002/ijc.28775CrossRefPubMed

Marcus A, Gowen BG, Thompson TW, Iannello A, Ardolino M et al (2014) Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol 122:91–128. https://doi.org/10.1016/B978-0-12-800267-4.00003-1CrossRefPubMedPubMedCentral

Bléry M, Vivier E (2018) NKG2D–MICA interaction: a paradigm shift in innate recognition. J Immunol 200:2229–2230. https://doi.org/10.4049/jimmunol.1800176CrossRefPubMed

Zingoni A, Molfetta R, Paolini R, Soriani A, Fionda C, Cippitelli M, Santoni A (2018) NKG2D and its ligands: “One for All, All for One.” Front Immunol 9:476. https://doi.org/10.3389/fimmu.2018.00476CrossRefPubMedPubMedCentral

Dhar P, Wu J (2018) NKG2D and its ligands in cancer. Curr Opin Immunol 51:55–61. https://doi.org/10.1016/j.coi.2018.02.004CrossRefPubMedPubMedCentral

Hamada S, Caballero-Benitez A, Duran KL, Stevens AM, Spies T, Groh V (2017) Soluble MICB in plasma and urine explains population expansions of NKG2D+CD4 T cells in patients with juvenile-onset systemic lupus erythematosus. Open J Immunol 7:1–17. https://doi.org/10.4236/oji.2017.71001CrossRefPubMedPubMedCentral

10.

Morvan MG, Champsaur M, Reizis B, Lanier LL (2017) Chronic in vivo interaction of dendritic cells expressing the ligand Rae-1e with NK cells impacts NKG2D expression and function. Immunohorizons 1:10–19. https://doi.org/10.4049/immunohorizons.1700004CrossRefPubMed

11.

Tamaki S, Kawakami M, Ishitani A, Kawashima W, Kasuda S, Yamanaka Y, Shimomura H, Imai Y, Nakagawa Y, Hatake K, Kirita A (2010) Soluble MICB serum levels correlate with disease stage and survival rate in patients with oral squamous cell carcinoma. Anticancer Res 30(10):4097–4101PubMed

12.

Groh V, Wu J, Yee C, Spies T (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation Nature 419(6908):734–738. https://doi.org/10.1038/nature01112

13.

Zhang Z, Liu S, Zhang B, Qiao L, Zhang Y, Zhang Y (2020) T cell dysfunction and exhaustion in cancer. Front Cell Dev Biol 8:17. https://doi.org/10.3389/fcell.2020.00017ADSCrossRefPubMedPubMedCentral

14.

Feng X, Menga M, Lia H, Gaoa Y, Songa W, Dia R, Lia Z, Zhanga X, Zhanga M (2023) T-cell dysfunction in natural killer/T-cell lymphoma. Oncoimmunol 12(1):2212532. https://doi.org/10.1080/2162402X.2023.2212532CrossRef

15.

Ray-Coquard I, Cropet C, Van Glabbeke M et al (2009) Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 69(13):5383–5391. https://doi.org/10.1158/0008-5472.CAN-08-3845CrossRefPubMedPubMedCentral

16.

Germain C, Devi-Marulkar P, Knockaert S, Biton J, Kaplon H, Letaïef L et al (2021) Tertiary lymphoid structure-B cells narrow regulatory T cells impact in lung cancer patients. Front Immunol 12:626776. https://doi.org/10.3389/fimmu.2021.626776CrossRefPubMedPubMedCentral

17.

Vela-Ojeda J, Perez-Retiguin FC, Olivas-Bejarano AC, Garcia-Ruiz Esparza MA, Garcia-Chavez J et al (2021) Clinical relevance of NKT cells and soluble MIC-A in Hodgkin lymphoma. Leuk Lymph 62(4):801–809. https://doi.org/10.1080/10428194.2020.1852473CrossRef

18.

Vassilakopoulos TP, Dimopoulou MN, Angelopoulou MK et al (2016) Prognostic implication of absolute lymphocyte to absolute monocyte count ratio in patients with classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent regimens. Oncologist 21(3):343–353. https://doi.org/10.1634/theoncologist.2015-0251CrossRefPubMedPubMedCentral

19.

Kharroubi DM, Nsouli G, Haroun Z (2023) Potential prognostic and predictive role of monocyte and lymphocyte counts on presentation in patients with diffuse large B-cell lymphomas. Cureus 15(3):e35654. https://doi.org/10.7759/cureus.35654CrossRefPubMedPubMedCentral

20.

William Vermi W, Micheletti A, Finotti G, Tecchio C, Calzetti F et al (2018) Slan+ monocytes and macrophages mediate CD20-dependent B-cell lymphoma elimination via ADCC and ADCP. Cancer Res 78(13):3544–3559. https://doi.org/10.1158/0008-5472.CAN-17-2344CrossRefPubMed

21.

Fong L, Engleman EG (2000) Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18:245–273. https://doi.org/10.1146/annurev.immunol.18.1.245CrossRefPubMed

22.

Chang KC, Huang GC, Jones D, Lin YH (2007) Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognosis. Clin Cancer Res 13(22):6666–6672. https://doi.org/10.1158/1078-0432.CCR-07-0504CrossRefPubMed

23.

Escriba-Garcia L, Alvarez-Fernandez C, Tellez-Gabriel M, Sierra J, Briones J (2017) Dendritic cells combined with tumor cells and alpha-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cells lymphoma. J Transl Med 15:115. https://doi.org/10.1186/s12967-017-1219-3CrossRefPubMedPubMedCentral

24.

Lin Z, Ma J, Ma Y, Li Q, Kang H et al (2023) Prognostic impact of peripheral natural killer cells in primary central nervous system lymphoma. Front Immunol 14:1191033. https://doi.org/10.3389/fimmu.2023.1191033CrossRefPubMedPubMedCentral

25.

Street SE, Hayakawa Y, Zhan Y, Lew AM, MacGregor D, Jamieson AM et al (2004) Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gamma-delta T cells. J Exp Med 199(6):879–884. https://doi.org/10.1084/jem.20031981CrossRefPubMedPubMedCentral

26.

Kunzmann V, Wilhelm M (2005) Anti-lymphoma effect of gammadelta T cells. Leuk Lymphoma 46:671–680. https://doi.org/10.1080/10428190500051893CrossRefPubMed

27.

Kabelitz D, Serrano R, Kouakanou L, Peters C, Kalyan S (2020) Cancer immunotherapy with gamma-delta T cells: many paths ahead of us. Cell Mol Immunol 17:925–939. https://doi.org/10.1038/s41423-020-0504-xCrossRefPubMedPubMedCentral

28.

Xu C, Vries R, Visser L et al (2010) Expression of CD1d and presence of invariant NKT cells in classical Hodgkin lymphoma. Am J Hematol 85(7):539–541. https://doi.org/10.1002/ajh.21743CrossRefPubMedPubMedCentral

29.

Renukaradhya GJ, Sriram V, Du W, Gervay-Hague J, Kaer LV, Brutkiewicz RR (2006) Inhibition of antitumor immunity by invariant natural killer T cells in a T-cell lymphoma model in vivo. Int J Cancer 118:3045–3053. https://doi.org/10.1002/ijc.21764CrossRefPubMed

30.

Hayakawa Y, Kelly JM, Westwood JA et al (2002) Cutting edge: Tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J Immunol 169:5377–5381. https://doi.org/10.4049/jimmunol.169.10.5377CrossRefPubMed

31.

Chitadze G, Lettau M, Bhat J et al (2013) Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the “a disintegrin and metalloproteases” 10 and 17. Int J Cancer 133:1557–1566. https://doi.org/10.1002/ijc.28174CrossRefPubMed

32.

Fernandez-Messina L, Ashiiru O, Boutet P et al (2010) Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands. J Biol Chem 285(12):8543–8551. https://doi.org/10.1074/jbc.M109.045906CrossRefPubMedPubMedCentral

33.

Belting L, Homberg N, Przewoznik M, Brenner C, Riedel T et al (2015) Critical role of the NKG2D receptor for NK cell-mediated control and immune escape of B-cell lymphoma. Eur J Immunol 45:2593–2601. https://doi.org/10.1002/eji.201445375CrossRefPubMed

34.

Dulphy N, Berrou J, Campillo JA, Bagot M, Benussan A, Toubert A (2009) NKG2D ligands expression and NKG2D-mediated NK activity in Sezari patients. J Invest Dermatol 129:359–364. https://doi.org/10.1038/jid.2008.256CrossRefPubMed

Titel: Lymphocyte subsets and soluble forms of MIC-A and MIC-B are prognostic factors in non-Hodgkin lymphoma patients
verfasst von: Ana Cristina Olivas-Bejarano
Laura Arcelia Montiel-Cervantes
Flor del Carmen Perez-Retiguin
Socrates Garcia-Gutierrez
Teresita Rocio Cruz-Hernandez
Ruth Angelica Lezama-Palacios
Elba Reyes-Maldonado
Jorge Vela-Ojeda
Publikationsdatum: 13.12.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 4/2024
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-023-05583-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2024

Decitabine-containing conditioning improved outcomes for children with higher-risk myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation

Association of a decreased platelet count with poor survival in patients with adult secondary hemophagocytic lymphohistiocytosis

Healthcare resource utilization of patients with warm autoimmune hemolytic anemia initiating first line therapy of oral corticosteroids with or without rituximab

Correction to: One disease, two faces: clonally-related AML and MPDCP with skin involvement

Successful treatment of a B/T MPAL patient by chemo-free treatment with venetoclax, azacitidine, and blinatumomab